Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | C1R | P00736 | 1/20 | 0.68 |
| ▸ | ELANE | P08246 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333007 | 0.94 | RAB9A (0.69) | NPC1RAB9AC1RELANEKDM4E | |
| SCHEMBL914389 | 0.91 | ALDH1A1 (0.61) | NPC1RAB9AC1RELANEKDM4E | |
| SCHEMBL12744508 | 0.89 | NPC1 (0.73) | NPC1RAB9AC1RELANEKDM4E | |
| SCHEMBL914149 | 0.87 | RAB9A (0.61) | NPC1RAB9AC1RELANEKDM4E | |
| SCHEMBL6567424 | 0.86 | ELANE (0.62) | NPC1RAB9AC1RELANEKDM4E | |
| SCHEMBL914708 | 0.86 | KDM4E (0.56) | NPC1RAB9AC1RELANEKDM4E | |
| SCHEMBL10780103 | 0.85 | ELANE (0.77) | NPC1RAB9AC1RELANEKDM4E | |
| SCHEMBL10781834 | 0.83 | ELANE (0.74) | NPC1RAB9AC1RELANEKDM4E | |
| SCHEMBL13137740 | 0.83 | HPN (0.54) | NPC1RAB9AC1RELANEKDM4E | |
| SCHEMBL914482 | 0.83 | NPC1 (1.00) | NPC1RAB9AELANEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10993938-B2 | Lactam compound, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-05-04 | — | — | US | disclosed |
| US-20210033886-A1 | LENS FOR SPECTACLES AND SPECTACLES | FUJIFILM CORPORATION (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2020-01-30 | — | — | US | disclosed |
| US-8304538-B2 | Method of producing benzoxazinone-based compound | FUJIFILM CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304538-B2 | Method of producing benzoxazinone-based compound | FUJIFILM CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20110015314-A1 | ULTRAVIOLET ABSORBENT AND PRODUCTION METHOD OF THE SAME | FUJIFILM CORPORATION (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015314-A1 | ULTRAVIOLET ABSORBENT AND PRODUCTION METHOD OF THE SAME | FUJIFILM CORPORATION (JP) | 2011-01-20 | — | — | US | disclosed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20100256362-A1 | METHOD OF PRODUCING BENZOXAZINONE-BASED COMPOUND | FUJIFILM CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256362-A1 | METHOD OF PRODUCING BENZOXAZINONE-BASED COMPOUND | FUJIFILM CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| WO-2009041715-A1 | METHOD OF PRODUCING BENZOXAZINONE-BASED COMPOUND | FUJIFILM CORPORATION (JP) | 2009-04-02 | — | — | WO | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | NPC1 4151/4885RAB9A 3514/4885C1R 202/4885 |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | FURIN, PEPD, PIN1 | NPC1 810/4885RAB9A 1387/4885C1R 1184/4885 |
| US-10993938-B2 | Lactam compound, preparation method and use thereof | FURIN, PEPD, PIN1 | NPC1 810/4885RAB9A 1387/4885C1R 1184/4885 |
| US-20110015314-A1 | ULTRAVIOLET ABSORBENT AND PRODUCTION METHOD OF THE SAME | SLC40A1, F2, SLC19A1 | NPC1 491/4885RAB9A 1212/4885C1R 73/4885 |
| US-20100256362-A1 | METHOD OF PRODUCING BENZOXAZINONE-BASED COMPOUND | SDHA, CYP4X1, SDHB | NPC1 2972/4885RAB9A 1686/4885C1R 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.